Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jonathan Juco

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Archives of Pathology and Laboratory Medicine

Medicine

Forensic Medicine

Pathology

Medical Laboratory Technology

2019

English

Interchangeability of PD-L1 Laboratory-Developed Test by 22C3 Antibody Concentrate Among Ihc Platforms in Gastric Cancer

English

Related publications

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-Naive Programmed Death Ligand 1–Positive Lung Cancer

Journal of Thoracic Oncology

English

Expression of Programmed Cell Death-Ligand 1 and Its Correlation With Clinical Outcomes in Gliomas

Oncotarget

Oncology

2016

English

Clinicopathological Significance and Prognostic Implication of Programmed Death-1 Ligand 2 Expression in Colorectal Cancer

International Journal of Biological Markers

Oncology

Cancer Research

Clinical Biochemistry

English

Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy

Matters

2017

English

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

English

Programmed Death-Ligand 1 Expression and Its Correlation With Clinicopathological Parameters in Gallbladder Cancer

Journal of Pathology and Translational Medicine

English

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

Frontiers in Oncology

Cancer Research

Oncology

2019

English

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

English

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Journal of Cancer

Oncology

2017

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jonathan Juco

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Interchangeability of PD-L1 Laboratory-Developed Test by 22C3 Antibody Concentrate Among Ihc Platforms in Gastric Cancer

Related publications

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-Naive Programmed Death Ligand 1–Positive Lung Cancer

Expression of Programmed Cell Death-Ligand 1 and Its Correlation With Clinical Outcomes in Gliomas

Clinicopathological Significance and Prognostic Implication of Programmed Death-1 Ligand 2 Expression in Colorectal Cancer

Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

Programmed Death-Ligand 1 Expression and Its Correlation With Clinicopathological Parameters in Gallbladder Cancer

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma